Drug
Ropeginterferon alfa-2b (BESREMi®)
Ropeginterferon alfa-2b (BESREMi®) is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting1
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
not_yet_recruiting133%
active_not_recruiting133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
not_yet_recruiting
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
NCT07282132
recruitingphase_2
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
NCT06770842
active_not_recruitingphase_3
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
NCT06514807
Clinical Trials (3)
Showing 3 of 3 trials
NCT07282132
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
NCT06770842Phase 2
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
NCT06514807Phase 3
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3